GlaxoSmithKline PLC (NYSE:GSK)

41.19
Delayed Data
As of Aug 23
 +0.21 / +0.51%
Today’s Change
36.41
Today|||52-Week Range
42.47
+7.80%
Year-to-Date
Top Analyst Reports for U.S. Bancorp, Duke Energy & Glaxo
Aug 23 / Zacks.com - Paid Partner Content
Better Buy: Eli Lilly vs. GlaxoSmithKline
Aug 18 / MotleyFool.com - Paid Partner Content
Pharma Stock Roundup: ABBV's Rinvoq Gets FDA Nod, BAYRY to Sell Animal Health Unit
Aug 23 / Zacks.com - Paid Partner Content
Ionis Pharmaceuticals Looks to Partners to Pay the Bills
Aug 14 / MotleyFool.com - Paid Partner Content
Glaxo Submits First Regulatory Application for Daprodustat
Aug 22 / Zacks.com - Paid Partner Content
Should Value Investors Consider GlaxoSmithKline (GSK) Stock?
Aug 13 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close40.98
Today’s open41.42
Day’s range41.07 - 41.73
Volume3,375,531
Average volume (3 months)2,402,858
Market cap$102.8B
Data as of 6:30pm ET, 08/23/2019

Growth & Valuation

Earnings growth (last year)+143.10%
Earnings growth (this year)-7.35%
Earnings growth (next 5 years)+4.00%
Revenue growth (last year)+5.72%
P/E ratio18.9
Price/Sales2.31
Price/Book18.26

Competitors

 Today’s
change
Today’s
% change
LLYEli Lilly and Co-2.10-1.88%
SNYSanofi+0.01+0.02%
ABBVAbbVie-1.55-2.30%
NVONovo Nordisk-0.43-0.82%
Data as of 6:30pm ET, 08/23/2019

Financials

Next reporting dateOctober 23, 2019
EPS forecast (this quarter)$0.78
Annual revenue (last year)$41.1B
Annual profit (last year)$4.8B
Net profit margin11.75%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chief Executive Officer &
Executive Director
Emma Walmsley
Chief Financial Officer &
Executive Director
Iain James Mackay
Corporate headquarters
Brentford, Greater London

Forecasts